Remo Panaccione

Remo Panaccione

Auto-generated profile, based on publicly available information

Remo Panaccione

Division of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary , Calgary, Alberta

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
RPRemo Panaccione
Remo Panaccione
SGSubrata Ghosh
Subrata Ghosh
SMStephen Middleton
Stephen Middleton
JMJuan R. Márquez
Juan R. Márquez
BSBoyd B. Scott
Boyd B. Scott
PRPaul Rutgeerts
Paul Rutgeerts

30 April 2025 in Nature
Verified
Journal Article
Open access
PDF file
LHLindsay Hracs
Lindsay Hracs
JWJoseph W. Windsor
Joseph W. Windsor
JGJulia Gorospe
Julia Gorospe
MCMichael Cummings
Michael Cummings
SCStephanie Coward
Stephanie Coward
GKGilaad Kaplan
Gilaad Kaplan
During the twentieth century, inflammatory bowel disease (IBD) was considered a disease of early industrialized regions in North America, Europe and Oceania1. At the turn of the twenty-first century, IBD incidence increased in newly industrialized and emerging regions in Africa, Asia and Latin America, while the prevalence in early industrialized regions continued to grow steadily2,3,4. Changes in the incidence and prevalence denote the evolution of IBD across four epidemiologic stages: stage 1 (emergence), characterized by low incidence and prevalence; stage 2 (acceleration in incidence), marked by rapidly rising incidence and low prevalence; and stage 3 (compounding prevalence), where the incidence decelerates, plateaus or declines while the prevalence steadily increases. A fourth stage (prevalence equilibrium) has been proposed in which the prevalence slope plateaus due to demographic shifts in an ageing IBD population, but it has not yet been evidenced. To date, these stages have remained theoretical, lacking specific numerical indicators to define transition points. Here, using real-world data from 522 population-based studies encompassing 82 global regions and spanning more than a century (1920–2024), we show spatiotemporal transitions across stages 1–3 and model stage 4 progression. Understanding the evolution of IBD across epidemiologic stages enables healthcare systems to better anticipate the future worldwide burden of IBD.

2 September 2020 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
ELEdward Loftus
Edward Loftus
BFBrian G. Feagan
Brian G. Feagan
RPRemo Panaccione
Remo Panaccione
JCJean‐Frédéric Colombel
Jean‐Frédéric Colombel
WSWilliam J. Sandborn
William J. Sandborn
SVSeverine Vermeire
Severine Vermeire
Summary: Background: Vedolizumab, a gut‐selective α4β7 integrin antibody, is approved for moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).Aim: To report the final results from the vedolizumab GEMINI long‐term safety (LTS) study.Methods: The phase 3, open‐label GEMINI LTS study (initiated May 2009) enrolled patients with UC or CD from four prior clinical trials and vedolizumab‐naïve patients. Vedolizumab LTS was evaluated; efficacy and patient‐reported outcomes were exploratory endpoints.Results: Enrolled patients (UC, n = 894; CD, n = 1349) received vedolizumab 300 mg IV every 4 weeks; median cumulative exposure was 42.4 months (range: 0.03‐112.2) for UC and 31.5 months (range: 0.03‐100.3) for CD. Over 8 years, adverse events (AEs) occurred in 93% (UC) and 96% (CD) of patients, with UC (36%) and CD (35%) exacerbations most frequent. Serious AEs were reported for 31% (UC) and 41% (CD) of patients. Vedolizumab discontinuation due to AEs occurred in 15% (UC) and 17% (CD) of patients. There were no new trends for infections, malignancies, infusion‐related reactions, or hepatic events, and no cases of progressive multifocal leukoencephalopathy. Of the ten deaths (UC, n = 4; CD, n = 6), two were considered drug‐related by local investigators (West Nile virus infection‐related encephalitis and hepatocellular carcinoma). Continuous vedolizumab maintained clinical response long‐term, with 33% (UC) and 28% (CD) of patients in clinical remission at 400 treatment weeks.Conclusions: The safety profile of vedolizumab remains favourable with no unexpected or new safety concerns. These results further establish the safety of vedolizumab and support its long‐term use (NCT00790933/EudraCT 2008‐002784‐14).

2 March 2017 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
CMC. Ma
C. Ma
RFR. N. Fedorak
R. N. Fedorak
GKG. G. Kaplan
G. G. Kaplan
LDL. A. Dieleman
L. A. Dieleman
SDS. M. Devlin
S. M. Devlin
RPR. Panaccione
R. Panaccione
Summary: Background: Ustekinumab is a monoclonal antibody targeting interleukins‐12 and ‐23, with efficacy in Crohn's disease (CD) demonstrated in clinical trials.Aim: To assess the real‐world clinical, endoscopic and radiographic response and remission outcomes achieved with ustekinumab in medically‐refractory CD.Methods: A retrospective multicentre cohort study was performed on CD patients receiving ustekinumab between 2011 and 2016. The primary outcome was achievement of clinical and objective steroid‐free response and remission at 3, 6 and 12 months. Clinical response and remission were defined by reduction in Harvey Bradshaw Index (HBI) of ≥3 points and an HBI ≤4 points respectively. Objective response was defined by improvement in endoscopic or radiographic CD, as assessed by ileocolonoscopy, contrast‐enhanced ultrasound or CT/MR enterography. Objective remission was defined by endoscopic mucosal healing or complete resolution of inflammatory parameters on radiographic assessment.Results: A total of 167 CD patients were treated with ustekinumab. 95.2% (159/167) previously failed anti‐TNF therapy. Median follow‐up was 45.6 weeks (IQR: 24.4–88.9). At 3 months, clinical response was achieved in 38.9% (65/167) and remission in 15.0% (25/167) of patients. At 6 months, clinical response was achieved in 60.3% (91/151) and remission in 25.2% (38/151) of patients. At 12 months, clinical response was achieved in 59.5% (66/111) and remission in 27.9% (31/111) of patients. Endoscopic or radiographic response was demonstrated in 54.5% (67/123) at 6 months and 55.8% (48/86) of patients at 12 months.Conclusions: Ustekinumab is an effective therapeutic option for inducing and maintaining clinical, endoscopic and radiographic response in patients with Crohn's disease failing anti‐TNF therapy.

22 September 2013 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
RPR. Panaccione
R. Panaccione
JCJ.‐F. Colombel
J.‐F. Colombel
WSW. J. Sandborn
W. J. Sandborn
GDG. D'HAens
G. D'HAens
QZQ. Zhou
Q. Zhou
ARA. M. Robinson
A. M. Robinson
Summary: Background: Therapies that maintain remission for patients with Crohn's disease are essential. Stable remission rates have been demonstrated for up to 2 years in adalimumab‐treated patients with moderately to severely active Crohn's disease enrolled in the CHARM and ADHERE clinical trials.Aim: To present the long‐term efficacy and safety of adalimumab therapy through 4 years of treatment.Methods: Remission (CDAI <150), response (CR‐100) and corticosteroid‐free remission over 4 years, and maintenance of these endpoints beyond 1 year were assessed in CHARM early responders randomised to adalimumab. Corticosteroid‐free remission was also assessed in all adalimumab‐randomised patients using corticosteroids at baseline. Fistula healing was assessed in adalimumab‐randomised patients with fistula at baseline. As observed, last observation carried forward and a hybrid nonresponder imputation analysis for year 4 (hNRI) were used to report efficacy. Adverse events were reported for any patient receiving at least one dose of adalimumab.Results: Of 329 early responders randomised to adalimumab induction therapy, at least 30% achieved remission (99/329) or CR‐100 (116/329) at year 4 of treatment (hNRI). The majority of patients (54%) with remission at year 1 maintained this endpoint at year 4 (hNRI). At year 4, 16% of patients taking corticosteroids at baseline were in corticosteroid‐free remission and 24% of patients with fistulae at baseline had healed fistulae. The incidence rates of adverse events remained stable over time.Conclusions: Prolonged adalimumab therapy maintained clinical remission and response in patients with moderately to severely active Crohn's disease for up to 4 years. No increased risk of adverse events or new safety signals were identified with long‐term maintenance therapy. (clinicaltrials.gov number: NCT00077779).

22 April 2025 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Open access
PDF file
VSVirginia Solitano
Virginia Solitano
CBCharles N. Bernstein
Charles N. Bernstein
IDIris Dotan
Iris Dotan
ADAxel Dignass
Axel Dignass
RDRhondell Domilici
Rhondell Domilici
SDSilvio Danese
Silvio Danese
Inflammatory bowel disease (IBD) is a growing global health challenge affecting more than 7 million people worldwide. With increasing prevalence across all age groups, including children and adolescents, IBD places substantial strain on health-care systems and society, resulting in high direct medical costs, lost productivity and reduced quality of life. Despite therapeutic advances, suboptimal disease control and delays in timely diagnosis and adequate treatment persist. Regional disparities in health-care access contribute to these challenges, especially in low-income countries. Addressing these inequities is crucial for improving global IBD outcomes. Using a Delphi methodology, experts from clinical care, research, public health and advocacy (including patient representation) identified priorities across six domains (37 statements in total): epidemiology, care models, treatment strategies, education and awareness, patient and community engagement, and leadership to promote health equity. These priorities emphasize quantifying the burden of IBD, addressing health-care disparities, validating care models, exploring novel treatments, advancing education, engaging patients and advocating for health equity policies. The comprehensive approach seeks to optimize care models, promote patient engagement and ensure equitable access to health care. The identified priorities serve as a guide for both clinical and non-clinical researchers, and funders dedicated to IBD-related initiatives, fostering international collaboration to improve IBD management and reduce its impact globally.